DICE Therapeutics, Inc.
400 East Jamie Court
South San Francisco
About DICE Therapeutics, Inc.
At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs.
The combination of our core technology with additional, unique biophysical insights has enabled DiCE to target protein-protein interactions with small molecules. In doing so, DiCE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.
Located in South San Francisco, we've built a team of experienced industry professionals dedicated to innovation in immunology drug development.
13 articles with DICE Therapeutics, Inc.
DICE Therapeutics, Inc. (Nasdaq: DICE) today reported financial results and business highlights for the third quarter ended September 30, 2022.
DICE Therapeutics, Inc. announced that management will present at the following investor conferences.
DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, reported financial results and business highlights for the second quarter ended June 30, 2022.
DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis
DICE Therapeutics, Inc. (Nasdaq: DICE), today announced the completion of enrollment in the Company’s Phase 1 clinical trial of DC-806 in healthy volunteers and psoriasis patients.
DICE Therapeutics, Inc. announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:30 p.m. ET.
DICE Therapeutics, Inc. reported financial results and business highlights for the first quarter ended March 31, 2022.
DICE Therapeutics, Inc. today announced that management will present at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 1:20 p.m. PT / 4:20 p.m. ET.
DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced the appointment of Mary Riley as general counsel and the additions of Lisa Bowers and Mittie Doyle, M.D., FACR, to DICE’s board of directors.
8/25/2021The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.
DiCE Molecules today announced the completion of its $60 million Series C-1 financing.
Biopharma companies raking in the cash with investment rounds and IPO announcements.
Jake Simson, Ph.D., joins Board of Directors Financing proceeds will support the progression of the Company’s first-in-class, oral IL-17 antagonist into clinical trials and advancement of its PPI antagonist pipeline
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.